Biocon Share Price in Focus Today: Biocon Gets FDA Approval for Bevacizumab Biosimilar

Updated: 11 Apr 2025 • 12:07 pm

Posted by:

Biocon Share Price in Focus Today: Biocon Gets FDA Approval for Bevacizumab Biosimilar

Biocon Share Price is up by 3.41% or ₹10.30, reaching ₹316.60 today on 11th April 2025. Based on the recent news updates, investors gained high confidence in Biocon shares for the near and long term.

Share Market Today, Stocks in news: Biocon Biologics Limited, a subsidiary of Biocon Limited, has received an FDA approval for Jobevne (Bevacizumab Biosimilar) for cancer therapy. The approval was obtained on 10th April 2025, marking the company’s 7th approval in the United States. It strengthens Biocon Limited’s leadership in affordable oncology solutions.

Table of Contents

Strong Clinical Evidence for FDA Approval

Here are the elements that influenced the FDA’s decision to approve Biocon’s Bevacizumab Biosimilar:

Pharmacokinetics
Immunogenicity
Nonclinical and Functional Data
Safety and Efficacy
Structural and Analytical Similarity

FDA’s approval confirmed no clinically meaningful differences between Jobevne and Avastin. It met the high standards required for biosimilar approval in the United States.

What Biocon’s CEO Says?

“This marks our third U.S. FDA approval for an oncology biosimilar and the seventh overall. It significantly strengthens our oncology portfolio and reiterates our commitment to providing affordable access to life-saving biologics in the U.S. and globally,” ~ Shreehas Tambe (CEO & Managing Director of Biocon Biologics).

Biocon Biologics: Leading Biosimilar Innovation

Biocon operates in 120+ countries and acts as a global trailblazer in biosimilar and insulin manufacturing. Its end-to-end capabilities, from research development to commercialisation, make it one of the few companies worldwide capable of delivering lab-to-market biosimilar innovation at scale. The global infrastructure of Biocon includes:

R&D Centers
Strategic Alliances
State-of-the-Art Manufacturing Units

Biocon Biologics Limited is strategically positioned to emerge as a dominant force in the US Biosimilar market, which is projected to reach $40 billion by 2030.

Summary

The FDA approval of Jobevne is a major achievement for both Biocon Biologics and the global healthcare community. With biosimilars playing an increasingly vital role in reducing healthcare expenses, Biocon’s expanding presence in critical therapeutic segments such as cancer ensures that patients across the United States and the globe have greater access to life-saving therapies.

Biocon Biologics’ latest achievement brings fresh confidence to the future of biosimilar drugs, which are low-cost, effective, and available.

For live stocks updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.